![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
May 08,2024
Xgene Pharmaceutical Pty Ltd. Announced the Enrollment of the First Cohort in the Phase I clinical trial of XG2002 capsules, a novel selective TRPM8 channel blocker.
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
April 08,2024
Xgene Pharmaceutical Pty Ltd. Announced that XG005 Phase II Clinical Trial of Keen Osteoarthritis in China Has Completed the Enrollment of Target Subjects
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
March 11,2024
Xgene Pharmaceutical Pty Ltd. Receives HREC’s approval to initiate a First-In-Human (FIH) trial of its innovative analgesic product XG2002
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
August 23,2023
Xgene Pharmaceutical Inc. Announces Dosing of First Patient in a Phase 2b/3 Trial of XG005 for the Treatment of Pain Following Bunionectomy Surgery.
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
April 26,2023
Xgene Pharmaceutical Announces Positive Top-Line Results from Phase 1b/2a Trial of Topical Gel XG004 for the Treatment of Osteoarthritis (OA) Pain of the Knee
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
November 04,2021
Xgene Pharmaceutical secures $40m in Series C
![RaQUA2 RaQUA2](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/RaQUA2-1-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
September 22,2021
Xgene Pharmaceuticals Co. Ltd.and RaQualia Pharma Inc.have entered into a licensing agreement for a novel TRPM8 blocker discovered by RaQualia Pharma
![fda fda](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/fda-pfy8zgjizqbbyxzw4z3b6b0xqxh4xi86lr5cqpsot8.jpg)
April 22,2020
NDA Application of XG005 will follow a 505(B)(1) regulatory pathway
![News_04May2019 News_04May2019](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/News_04May2019-pfy8zgjizqbbyxzw4z3b6b0xqxh4xi86lr5cqpsot8.jpeg)
May 4, 2019
XGene Pharmaceutical Closed the B Plus
Round Financing
![News_25Oct2018 News_25Oct2018](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/News_25Oct2018-pfy8zgjizqbbyxzw4z3b6b0xqxh4xi86lr5cqpsot8.jpg)
October 25, 2018
XGene Pharmaceutical Closed US$20 Million B Round Financing